Lower Risk of Adverse Outcomes Seen in Obese With Heart Failure

Share this article:
Lower Risk of Adverse Outcomes Seen in Obese With Heart Failure
Lower Risk of Adverse Outcomes Seen in Obese With Heart Failure

(HealthDay News) – For both women and men with advanced heart failure, having a high body mass index (BMI) or waist circumference (WC) is associated with a reduced risk of adverse outcomes.

To investigate the role of obesity in the outcomes of men and women with heart failure, Adrienne L. Clark, from the David Geffen School of Medicine at the University of California Los Angeles, and colleagues followed a cohort of 2,718 patients with heart failure who had their BMI measured at baseline and 469 patients who had their WC measured.

The researchers found that, for men, the two-year event-free survival was better for high versus normal BMI and WC (63.2 vs. 53.5% and 78.8 vs. 63.1%, respectively). For women, high vs. normal BMI was associated with improved two-year event-free survival (67.1 vs. 56.6%), but survival was similar for high and normal WC. In multivariate analysis, for men and women, normal BMI and WC correlated with increased relative risk in the primary outcome of death, urgent heart transplantation, or ventricular assist device placement.

"In our study of patients with advanced systolic heart failure, obesity as indexed by high BMI and high WC was associated with better outcomes in men and women," the authors write. "To our knowledge, our study is the first to specifically demonstrate that the obesity paradox in terms of BMI and WC is applicable to men and women with heart failure."

Abstract
Full Text (subscription or payment may be required)

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs